Phosphoinositide 3-kinase (PI 3-kinase) was discovered because of its co- purification with activated protein-tyrosine kinases. Activation of this enzyme in vivo by growth factors and other cellular activators results in the production of PtdIns-3,4,5-P3, a lipid that is nominally absent in quiescent cells. The stimulation of PI 3-kinase has been implicated in a variety of cellular responses including cell growth, cell transformation, chemotaxis, membrane ruffling, activation of ribosomal S6 kinase, induction of fos, stimulation of glucose uptake, secretion of histamine, activation of ras, lysosomal degradation of receptors and irreversible aggregation of platelets. In several of these studies, the evidence for the importance of PI 3-kinase is quite strong. The yeast PI 3-kinase homolog (VPS34) is required for movement of proteins from the golgi to the vacuole. However, the biochemical mechanism by which this enzyme causes all or even any of these responses is still not understood. The goal of this research is to identify the biochemical pathway(s) by which PI 3-kinase mediates cellular responses. The hypothesis is that the lipid products of this enzyme directly bind to signaling proteins in the cytosol to nucleate specific event at the membrane where the lipid is generated. Two general approaches will be taken. 1) We will look for proteins that show selectivity in binding PtdIns-3,4,5-P3 and/or PtdIns- 3,4-P2 over the more abundant steroisomer PtdIns-4,5-P2. We have identified a subfamily of protein kinase C isoforms (PKCepsilon, PKCdelta and PKCcia) that bind PtdIns-3,4,5-P3 and PtdIns-3,4-P2 with high affinity and stereospecificity and will investigate the possibility that these enzymes are activated by PtdIns-3,4,5-P3 and/or Ptdins-3,4-P2 in vivo. Other proteins that have been reported to bind PtdIns-4,5-P2 will be investigated for their ability to bind PtdIns-3,4,5-P3 and/or PtdIns-3,4-P2 in vitro (in particular actin severing, capping and bunding protein). Affinity columns will be used to isolate novel phosphoinositide-binding proteins. 2) We will also develop in vivo assays for the importance of PI 3-kinase in cellular responses. In particular, we will inject reagents that inhibit or mimic PI 3-kinase activation into single cells and monitor rapid responses that have been attributed to this enzyme (membrane ruffling, chemotaxis). The targets identified in part 1 can be tested in this system.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM041890-09
Application #
2392074
Study Section
Physiological Chemistry Study Section (PC)
Project Start
1995-04-01
Project End
1999-03-31
Budget Start
1997-04-01
Budget End
1998-03-31
Support Year
9
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Lundquist, Mark R; Goncalves, Marcus D; Loughran, Ryan M et al. (2018) Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Mol Cell 70:531-544.e9
Hopkins, Benjamin D; Pauli, Chantal; Du, Xing et al. (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499-503
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2018) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov 8:354-369
Waldhart, Althea N; Dykstra, Holly; Peck, Anderson S et al. (2017) Phosphorylation of TXNIP by AKT Mediates Acute Influx of Glucose in Response to Insulin. Cell Rep 19:2005-2013
Thorpe, Lauren M; Spangle, Jennifer M; Ohlson, Carolynn E et al. (2017) PI3K-p110? mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85?. Proc Natl Acad Sci U S A 114:7095-7100
Gupta, Amit; Anjomani-Virmouni, Sara; Koundouros, Nikos et al. (2017) PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. Mol Cell 65:999-1013.e7
Mathur, Deepti; Stratikopoulos, Elias; Ozturk, Sait et al. (2017) PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discov 7:380-390
Lee, Ho-Joon; Jedrychowski, Mark P; Vinayagam, Arunachalam et al. (2017) Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to Proliferation. Cell Rep 20:721-736
Matulonis, U A; Wulf, G M; Barry, W T et al. (2017) Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol 28:512-518

Showing the most recent 10 out of 164 publications